Showing 13 to 20 of 20 results
AstraZeneca Invests $2.5 Billion in Beijing R&D Center
AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global R&D center, partnering with three Chinese biotech companies and the Beijing Cancer Hospital, aiming to leverage China's life sciences ecosystem and expand its global reach.
AstraZeneca Invests $2.5 Billion in Beijing R&D Center
AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global R&D center, partnering with three Chinese biotech companies and the Beijing Cancer Hospital, aiming to leverage China's life sciences ecosystem and expand its global reach.
Progress
52% Bias Score
AstraZeneca Profits Soar Despite UK Investment Cancellation and China Crisis
AstraZeneca's 2024 annual profits jumped 38% to $8.7bn due to strong sales of cancer, lung, and immunology treatments; however, the company cancelled a \£450m UK investment after disagreements over state support, and faces a crisis in China with detained executives and potential fines.
AstraZeneca Profits Soar Despite UK Investment Cancellation and China Crisis
AstraZeneca's 2024 annual profits jumped 38% to $8.7bn due to strong sales of cancer, lung, and immunology treatments; however, the company cancelled a \£450m UK investment after disagreements over state support, and faces a crisis in China with detained executives and potential fines.
Progress
40% Bias Score
UK Economic Outlook Worsens Amid Fiscal Constraints and Inflation
The UK faces a deteriorating economic outlook, with £10 billion in fiscal space lost to low growth, high inflation, and interest rates, leading to potential emergency budget discussions and impacting the Bank of England's policy decisions.
UK Economic Outlook Worsens Amid Fiscal Constraints and Inflation
The UK faces a deteriorating economic outlook, with £10 billion in fiscal space lost to low growth, high inflation, and interest rates, leading to potential emergency budget discussions and impacting the Bank of England's policy decisions.
Progress
44% Bias Score
AstraZeneca Cancels £450m UK Vaccine Plant Expansion
AstraZeneca scrapped a £450 million UK vaccine plant expansion due to a reduced government funding offer following a change in planned research and development investment, disappointing the UK science minister and impacting 450 jobs.
AstraZeneca Cancels £450m UK Vaccine Plant Expansion
AstraZeneca scrapped a £450 million UK vaccine plant expansion due to a reduced government funding offer following a change in planned research and development investment, disappointing the UK science minister and impacting 450 jobs.
Progress
44% Bias Score
UK's SMR Delay: Overseas Competitors Gain Advantage
The UK government's slow approval process for Rolls-Royce's small modular reactors (SMRs) is allowing foreign competitors to gain a significant advantage, jeopardizing British engineering and jobs, while AstraZeneca's success highlights the need for greater support for domestic industries.
UK's SMR Delay: Overseas Competitors Gain Advantage
The UK government's slow approval process for Rolls-Royce's small modular reactors (SMRs) is allowing foreign competitors to gain a significant advantage, jeopardizing British engineering and jobs, while AstraZeneca's success highlights the need for greater support for domestic industries.
Progress
64% Bias Score
AstraZeneca's Q4 2024 Earnings Exceed Expectations, Driven by Strong Clinical Trial Results
AstraZeneca announced strong Q4 2024 and full-year results, with total revenue surging 24% to $14.9 billion in Q4 and 18% to $54.1 billion for the full year, driven by successful clinical trials and rising demand across all major therapy areas; CEO Pascal Soriot highlighted this as the start of a ca...
AstraZeneca's Q4 2024 Earnings Exceed Expectations, Driven by Strong Clinical Trial Results
AstraZeneca announced strong Q4 2024 and full-year results, with total revenue surging 24% to $14.9 billion in Q4 and 18% to $54.1 billion for the full year, driven by successful clinical trials and rising demand across all major therapy areas; CEO Pascal Soriot highlighted this as the start of a ca...
Progress
56% Bias Score
GSK CEO urges UK government to boost support for pharma industry
GSK's CEO Emma Walmsley says the UK government must increase support for its pharmaceutical industry to prevent it being overtaken by foreign rivals, following AstraZeneca's cancellation of a £450 million vaccine factory near Liverpool due to insufficient state support.
GSK CEO urges UK government to boost support for pharma industry
GSK's CEO Emma Walmsley says the UK government must increase support for its pharmaceutical industry to prevent it being overtaken by foreign rivals, following AstraZeneca's cancellation of a £450 million vaccine factory near Liverpool due to insufficient state support.
Progress
44% Bias Score
Labour's AstraZeneca Snub Threatens UK Science Hub Ambitions
Labour's refusal to support AstraZeneca's £450 million Liverpool vaccine plant clashes with their science goals, contrasting with US government support and potentially driving investment away from the UK.
Labour's AstraZeneca Snub Threatens UK Science Hub Ambitions
Labour's refusal to support AstraZeneca's £450 million Liverpool vaccine plant clashes with their science goals, contrasting with US government support and potentially driving investment away from the UK.
Progress
64% Bias Score
Showing 13 to 20 of 20 results